Organization
Monrovia
2 abstracts
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Relationship between ICOS and ICOS ligand RNA expression patterns with tumor type, tumor mutational burden, and clinically relevant immune checkpoints.Org: University of California San Diego, Moores Cancer Center, UC San Diego Health, La Jolla, CA, CanSino Biologics, Children's Oncology Group,